# Expanded Access for CC-486

> **NCT03723135** · — · APPROVED_FOR_MARKETING · sponsor: **Celgene**

## Conditions studied

- Acute Myelogenous Leukemia (AML)

## Interventions

- **DRUG:** CC-486

## Key facts

- **NCT ID:** NCT03723135
- **Lead sponsor:** Celgene
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** APPROVED_FOR_MARKETING
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2020-09-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03723135

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03723135, "Expanded Access for CC-486". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03723135. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*